Analysis of:
New Treatment Offers Relief from Chronic Back Pain - Study Suggests Safe Treatment for a Variety of Conditions (www.medicalnewstoday.com)
(1) Chronic back pain is a challenge to treat with limited options. (2) The emergence of new therapies to help support efforts at physiotherapy are certainly hopeful signs for those with refractory pain. (3) There are concerns about this specific treatment, PRF.
Analysis of:
New Test May Allow For Rapid Detection Of Salmonella In Meat (www.medicalnewstoday.com)
PCR analysis of meat for Salmonella was compared to traditional culture methods The PCR technique showed a relatively high sensitivity and specificity for the organism much more rapidly
Analysis of:
Sebivo(R) (Telbivudine) Approved in European Union as a New Treatment for Chronic Hepatitis B Patients (www.pipelinereview.com)
Telbivudine is a new option of treatment for patients with chronic hepatitis B.In the United States, approximately 1.2 million persons have chronic hepatitis B virus (HBV) infection and are sources for HBV transmission to others. Two billion people infected worldwide, and 350 million suffering...
Analysis of:
Brazil Bypasses Patent on U.S. AIDS Drug (www.reuters.com)
Newer, more efficacious antiretrovirals are emerging.Older treatments must be open in order to be competitive and continue in the market.
Analysis of:
Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented At AAN (www.medicalnewstoday.com)
Ideal treatment of Multiple Sclerosis is still ongoing. Interferons are only partially succesful in treating this condition. Alemtuzumab, a drug that was intended for the treatment of B-cell chronic lymphocytic leukemia proved to be useful in MS. It reduced significantly the risk of relapse and...
Analysis of:
Major phase 3 program planned for new antiplatelet drug (www.theheart.org)
(1) TRA-SCH 530348 has a novel mechanism of action. (2) Many antiplatelet agents (and anticoagulation therapies) are available with differences based on ability to prevent clotting and risk of systemic hemorrhage. (3) Unclear what the benefits or risks of new agents will be until assessed in controlled...
Analysis of:
Research Finds Newer Drug for Partial Epilepsy Is Superior But Old Tops New For Generalised Seizures (www.medicalnewstoday.com)
The article reports on a British study suggesting that lamotrigine and valproic acid are respectively the best first line drugs for partial and generalized onset epilepsy.
Analysis of:
Avicena Announces Patient Enrollment in National Institutes Of Health (NIH) Phase III Parkinson's Disease Trial (www.medicalnewstoday.com)
PD-02 is an ultra-pure form of creatine which may slow the progress of Parkinson’s Disease. A federal government sponsored phase III clinical trial has just begun to evaluate its efficacy.
Analysis of:
Suffering boomers want to fill Vioxx void (www.contracostatimes.com)
The article states that Cox-2 inhibitors may be making a comeback to treat arthritis pain
Analysis of:
FDA Approves Duloxetine for Anxiety (journals.elsevierhealth.com)
Duloxetine has received FDA approval for the treatment of generalized anxiety disorder, based on the results of three studies of more than 800 subjects.